Nephrocare Health Services Limited will participate in an investor conference hosted by PL Capital on September 29, 2026, at 1:00 pm IST. The event will take place at Trident BKC in Mumbai and involves one-on-one and group meetings with institutional investors.

The company disclosed this schedule in a filing to stock exchanges under Regulation 30 of the SEBI Listing Regulations. The interactions are intended to provide clarity on business operations using existing public data.

Meeting details

The specific logistics for the upcoming engagement are outlined below:

Disclosure compliance

Nephrocare stated that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company. The disclosure has been made available on the company's website for public reference.

Nephrocare Health Services approved the rationalisation and consolidation of its step-down subsidiaries in the Philippines on September 18, 2026. The move aims to simplify the corporate structure and enhance operational efficiency.

The Board of Directors sanctioned the proposal during a meeting held on Friday, September 18, 2026. The decision is subject to compliance with applicable laws and receipt of necessary statutory, regulatory, corporate, and other approvals in India and the Philippines.

Structural Rationalisation

The company operates its Philippine business through Nephrocare Health Care Services Philippines, Inc., a step-down subsidiary held via Nephrocare Health Services International Pte. Ltd. in Singapore. The group currently uses multiple wholly-owned subsidiaries for these operations.

The proposed consolidation will reduce the number of operating entities. Management stated this internal reorganisation is intended to streamline administrative and compliance processes, optimise costs, and strengthen governance oversight. The simplified structure is designed to be more scalable and aligned with the company’s international growth strategy.

No Change in Control

The transaction involves no third-party investors. There will be no change in the shareholding pattern of Nephrocare Health Services or in the ultimate ownership and control of the Philippine business.

Nephrocare PH will remain a step-down subsidiary through the Singapore entity. The company plans to account for the transaction as a common-control transaction under the applicable accounting framework. The restructuring does not envisage any specific benefit to the promoter or promoter group.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFDPOD2/ I/3762/2026 dated January 30, 2026.

Further updates regarding the rationalisation will be disclosed as required under the listing regulations.